A randomized trial just showed 25% more hair density in eight weeks — and the active ingredient was a tropical plant. Here is what that research actually means.

The trial was randomized and double-blind — neither participants nor assessors knew who received which formulation. Sixty adults between 18 and 60 were assigned to five groups, including a placebo. Each group applied one milliliter to the scalp nightly. Hair density, thickness, length, and shedding rate were measured at days 14, 28, 42, and 56. The lead researcher was Dr. Tsong Min Chang in Taipei; the study was conducted by Schweitzer Biotech Company (SBC). The conflict of interest — company-affiliated researchers reporting on a company product — is real and worth noting. The study design itself, however, is more rigorous than the vast majority of botanical hair care claims in circulation.

By day 56, the full-combination group showed approximately 25% higher hair density compared to the placebo group. The combination included Centella asiatica extracellular vesicles, caffeine, panthenol (provitamin B5), fibroblast growth factor 7 (FGF-7), and insulin-like growth factor 1 (IGF-1). The critical finding: results improved consistently as more ingredients were added. The group using only Centella vesicles showed gains. The group using Centella plus caffeine showed more. The full combination showed the most. This gradient strongly suggests the mechanism is synergistic — the botanical is not the whole answer, but it is a meaningful component of a combination that works.

The participants were healthy adults without diagnosed androgenetic alopecia. This is the most significant limitation: the results may not translate directly to people experiencing pattern hair loss, where DHT miniaturization has already compromised the follicle environment. The eight-week window captures early growth cycle changes but does not show whether density improvements persist beyond the trial. The study was not compared head-to-head against minoxidil or finasteride. And company involvement in the research is a legitimate reason to wait for independent replication before treating the numbers as definitive. This is promising evidence, not a proven treatment.

The botanical hair care conversation has suffered from a credibility problem: most ingredient claims rest on in-vitro data, traditional use citations, or brand-funded marketing. A randomized controlled trial — however imperfect — is a categorically different type of evidence. The Centella finding contributes to a growing body of controlled botanical research that includes the 2015 rosemary-versus-minoxidil study, the pumpkin seed oil trials, and the saw palmetto literature. Taken together, this research portrait suggests that the botanical approach to scalp health is not adjacent to the clinical approach. It is the same inquiry, using the same tools, arriving at results that deserve the same honest assessment.

Yes — gotu kola is the common name for Centella asiatica in Ayurvedic tradition. The same plant is known as ji xue cao in traditional Chinese medicine and brahmi in some regional contexts (though brahmi more commonly refers to Bacopa monnieri, a separate plant). The botanical name Centella asiatica is the unambiguous identifier — when reading an ingredient label, look for that.

Honestly: not directly. The participants were healthy adults without diagnosed AGA. The mechanisms that produced density improvements in healthy follicle environments may also benefit compromised follicles — the anti-inflammatory and circulatory effects are relevant across hair loss types — but the study does not demonstrate this. For people with androgenetic alopecia, Centella is a reasonable addition to a ritual that already addresses DHT (through ingredients like rosemary, saw palmetto, or medical treatment), not a replacement for that DHT strategy.

Yes — and the trial suggests this is precisely the right approach. Centella addresses collagen, inflammation, and circulation. Rosemary adds DHT inhibition and additional circulatory support. Castor oil contributes ricinoleic acid and a different anti-inflammatory pathway. These ingredients do not compete — they address complementary mechanisms. A formulation that combines several of them is closer to what the research supports than any single-ingredient application.

The safety profile of Centella asiatica topically is well-established — it has been in clinical use in skincare and wound healing for decades with a strong tolerability record. The hair density evidence is newer and would benefit from independent replication. Using a well-formulated Centella-containing scalp product while that replication occurs is a reasonable position: the downside risk is low, the existing evidence is the most rigorous produced for this ingredient category, and the mechanisms proposed are biologically plausible.

Because the evidence does. Rosemary, Centella, ginger, hibiscus, castor oil — these are not ingredients chosen for marketing appeal. They are the botanicals with the most consistently supported mechanisms across circulatory, anti-inflammatory, DHT-modulating, and regenerative pathways. The convergence of traditional use and controlled research on this same set of plants is not coincidence. It is what the botanical approach to scalp health has been building toward for a long time.